Conference Track

Hepatitis and Opportunistic Coinfections

Source: CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Improved Outcomes in SMART Study Patients Resuming ART but With Residual Effects of Treatment Interruption
ACTG 5178 (SLAM-C): No Benefit Shown With Peginterferon alfa-2a Monotherapy in HIV/HCV-Coinfected Nonresponders to Peginterferon alfa-2a Plus Ribavirin
Achieving SVR Reduces Risk for Liver-Related Morbidity and Mortality in HIV/HCV-Coinfected Individuals
HCV Recurrence After Achieving SVR Likely Due to HCV Reinfection, Not Late Relapse, in HIV/HCV-Coinfected Homosexual Men
Further Evidence of Anti-HIV Activity, M184V Selection With Entecavir Monotherapy in Treatment-Naive and Treatment-Experienced HIV/HBV-Coinfected Patients
Model for End Stage Liver Disease Score Predicts Risk of Mortality Before Liver Transplantation in HIV-Infected Individuals
ACTG A5164: Immediate Antiretroviral Therapy Initiation in Patients Presenting With Acute OIs Associated With Reduced Clinical Progression and Death
Reinfection Primary Cause for Development of Multidrug- and Extensively Drug–Resistant TB Among HIV/TB-Coinfected Patients
Higher Mortality in HIV/TB-Coinfected Patients Initiating HAART Explained by Malnutrition and Advanced HIV Disease
High Early HIV-Related Mortality in Resource-Limited Setting Due to Late HAART Initiation, but Rarely to IRIS
Long-term Use of Trimethoprim/Sulfamethoxazole Appears to Prevent S. aureus Nasal Colonization in HIV-Infected Individuals
Rituximab for HIV-Related Non-Hodgkin’s Lymphoma Significantly Improves Survival Without Increased Mortality From Infection
Reduced Rates of SVR to Peginterferon plus Ribavirin in HIV/HCV-Coinfected Patients When Abacavir Used in Concomitant Antiretroviral Regimen
Tenofovir Use Associated With Improved Response to Peginterferon Plus Ribavirin in HIV/HCV-Coinfected Patients

Expert Analysis

Hepatitis and Opportunistic Coinfections

Faculty:

Richard E. Chaisson, MD
Bruce Polsky, MD
Jürgen K. Rockstroh, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize new data on the optimal timing of antiretroviral therapy in patients who present with acute opportunistic infections
Discuss the results of recent studies on the management of chronic hepatitis B and chronic hepatitis C in HIV-infected patients
Recount new findings on tuberculosis coinfection in HIV-infected patients
Describe recent insights regarding diverse clinical complications in HIV-infected patients, including Staphylococcus aureus and malignancies

CME CREDIT INFORMATION

Release Date: 03/21/08

Expiration Date: 03/20/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing CE credits

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.